A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration (clinicaltrials.gov) - Sep 25, 2026 - P1 | N=84 | Recruiting | Sponsor: Bristol-Myers Squibb | Not yet recruiting ➔ Recruiting
Enrollment open • Alzheimer's Disease • CNS Disorders
|